← Back to Screener
Crinetics Pharmaceuticals, Inc. (CRNX)
Price$40.25
Favorite Metrics
Price vs S&P 500 (26W)-17.49%
Price vs S&P 500 (4W)5.77%
Market Capitalization$4.29B
All Metrics
Book Value / Share (Quarterly)$10.38
P/TBV (Annual)6.76x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.53%
Cash Flow / Share (Quarterly)$-4.01
Price vs S&P 500 (YTD)-16.06%
Net Profit Margin (TTM)-6046.22%
EPS (TTM)$-4.94
10-Day Avg Trading Volume0.97M
EPS Excl Extra (TTM)$-4.94
Revenue Growth (5Y)156.00%
EPS (Annual)$-4.95
ROI (Annual)-46.90%
Gross Margin (Annual)86.02%
Net Profit Margin (5Y Avg)-10707.53%
Cash / Share (Quarterly)$10.75
ROA (Last FY)-41.32%
Revenue Growth TTM (YoY)640.71%
EBITD / Share (TTM)$-5.46
ROE (5Y Avg)-38.69%
Operating Margin (TTM)-6714.77%
Cash Flow / Share (Annual)$-4.01
P/B Ratio4.33x
P/B Ratio (Quarterly)4.45x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)544.62x
ROA (TTM)-37.43%
EPS Incl Extra (Annual)$-4.95
Current Ratio (Annual)12.32x
Quick Ratio (Quarterly)12.09x
3-Month Avg Trading Volume1.19M
52-Week Price Return38.61%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.21
P/S Ratio (Annual)557.81x
Asset Turnover (Annual)0.01x
52-Week High$57.99
Operating Margin (5Y Avg)-11677.88%
EPS Excl Extra (Annual)$-4.95
CapEx CAGR (5Y)97.86%
Tangible BV CAGR (5Y)84.80%
26-Week Price Return-8.75%
Quick Ratio (Annual)12.09x
13-Week Price Return-26.02%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.32x
Enterprise Value$4,191.383
Revenue / Share Growth (5Y)104.27%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)15.19%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-6043.88%
Cash / Share (Annual)$10.75
3-Month Return Std Dev43.67%
Net Income / Employee (TTM)$-1
ROE (Last FY)-46.90%
EPS Basic Excl Extra (Annual)$-4.95
Receivables Turnover (TTM)0.68x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.94
Receivables Turnover (Annual)2.52x
ROI (TTM)-41.46%
P/S Ratio (TTM)557.81x
Pretax Margin (5Y Avg)-10667.85%
Revenue / Share (Annual)$0.08
Tangible BV / Share (Annual)$5.87
Price vs S&P 500 (52W)3.51%
Year-to-Date Return-11.92%
5-Day Price Return6.05%
EPS Normalized (Annual)$-4.95
ROA (5Y Avg)-34.62%
Net Profit Margin (Annual)-6046.22%
Month-to-Date Return12.89%
Cash Flow / Share (TTM)$-3.61
EBITD / Share (Annual)$-5.46
Operating Margin (Annual)-6714.77%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-38.69%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.94
P/TBV (Quarterly)3.90x
P/B Ratio (Annual)4.45x
Pretax Margin (TTM)-6043.88%
Book Value / Share (Annual)$10.38
Price vs S&P 500 (13W)-28.88%
Beta0.32x
Revenue / Share (TTM)$0.08
ROE (TTM)-41.46%
52-Week Low$25.83
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRNXCrinetics Pharmaceuticals, Inc. | 557.81x | 640.71% | — | — | $40.25 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company developing treatments for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly in patients with inadequate response to surgery or for whom surgery is not an option. The pipeline includes late-stage candidate atumelnant for adrenal disorders and CRN09682 targeting specific neuroendocrine tumors.